Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.

AdvanCell's $315M raise funds a lead-212 alpha-therapy bet on prostate cancer, differentiated by manufacturing control amid an actinium supply bottleneck.

• Oversubscribed $315M Series D: AdvanCell closed the raise in July, bringing in a high-quality syndicate to fund phase 2/3 readiness and U.S. manufacturing buildout.
• Lead-212 vs. actinium bet: AdvanCell targets lead-212 (10.6-hour half-life) alpha emitters over actinium-based rivals, citing thorium-228's greater abundance versus scarce actinium parent isotopes.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.